ArticleBreast cancer research : BCR2023
Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low.
Article in Breast cancer research : BCR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 52 citations in OpenAlex.
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.Nature medicine · 2024Trial
- Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Utilization of MRI-based radiomics nomogram for predicting HER2-zero, -low, and -overexpression breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Discordance between Breast and Axillary Responses After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Implications for Surgical De-Escalation.Annals of surgical oncology · 2026Article
- Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy.NPJ precision oncology · 2026Article
- SpatialESD: Spatial Ensemble Domain Detection in Spatial Transcriptomics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Research trends on nanomaterials in triple negative breast cancer (TNBC): a bibliometric analysis from 2010 to 2024.Drug delivery and translational research · 2026Article
- Comparison of Stromal Tumor-Infiltrating Lymphocyte (sTIL) Levels and Clinicopathological Features in Neoadjuvant-Naive HER2-Low and HER2-Negative Primary Breast Cancers.Medicina (Kaunas, Lithuania) · 2026Article
- Therapy as a State-Generator: Dynamic Phenotypic Landscapes and Adaptive Stress Circuits in Chemotherapy Resistance of Breast Cancer.Antioxidants (Basel, Switzerland) · 2026Review
- NeoProspect HER2-low: Response and Prognosis After Neoadjuvant Treatment in Patients with HER2-low Breast Cancer.Cureus · 2026Article
- Datopotamab deruxtecan in Chinese patients with heavily pretreated advanced or metastatic triple-negative breast cancer in the phase I/II TROPION-PanTumor02 study.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress.Anti-cancer agents in medicinal chemistry · 2026Review
- Unveiling immune-related gene signatures in triple negative breast cancer through integrated transcriptomic analysis.BioMedicine · 2026Article
- ECSCR functions as a potential tumor suppressor in breast cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- Focal hotspot and diffuse immune subtypes of tumor-infiltrating lymphocytes: AI-powered spatial clustering classification and its clinical relevance to HER2 expression in triple-negative breast cancer.Journal of translational medicine · 2025Article
- Changes in HER2, ER, PR, and Ki-67 in HER2-Negative Breast Cancer After Neoadjuvant Chemotherapy: A Case-Control Study.Current oncology (Toronto, Ont.) · 2025Article
- Bibliometric analysis of global research on breast cancer with HER2-low expression.Discover oncology · 2025Article
- Granulocyte colony-stimulating factor induced T-cell hyporesponsiveness via modulation of CD177Clinical and translational medicine · 2025Article
- Fusidic Acid Reverses Chemoresistance in Breast Cancer via Targeting DDX6 to Downregulate GSK-3β/β-Catenin Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancer.NPJ precision oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear.
methodsWe enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2
resultsCompared with HER2
conclusionsThis study suggests that HER2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.